STOCK TITAN

Eikon Therapeutics (EIKN) SEC Filings

EIKN NASDAQ

Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.

The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.

Rhea-AI Summary

Eikon Therapeutics, Inc. reported a third-quarter net loss of $86.112 million, compared with $71.139 million a year earlier, as research and development expense rose to $71.826 million from $59.313 million. Nine-month net loss was $257.479 million, versus $244.593 million in 2025, and net cash used in operating activities was $223.950 million, compared with $146.792 million.

At September 30, 2026, Eikon held $461.7 million in cash, cash equivalents and marketable securities; the company said it believes this balance will fund operations for at least one year from issuance of the financial statements. License agreements could require up to $630.0 million in development and regulatory milestones and up to $1.1 billion in sales milestones, plus tiered royalties based on licensed-product net sales. Eikon has no products approved for commercial sale and has never generated revenue from product sales. The company previously identified a material weakness in internal control over financial reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
quarterly report
-
Rhea-AI Summary

Eikon Therapeutics, Inc. reported third-quarter 2026 results and clinical updates. Among 65 efficacy-evaluable participants in TeLuRide-005, EIK1001 with pembrolizumab and chemotherapy had a 63.1% objective response rate and an 89.2% disease control rate at median follow-up of 17.2 months. Squamous and non-squamous cohorts had objective response rates of 72.4% and 55.6%, respectively.

As of September 30, 2026, cash, cash equivalents and marketable securities were $461.7 million; net cash used in operating activities was $224.0 million for the nine months. Eikon expects its current cash, cash equivalents and marketable securities to fund operations into the first quarter of 2028. Third-quarter net loss attributable to common stockholders was $86.1 million, versus $71.1 million a year earlier. R&D expenses were $71.8 million and G&A expenses were $18.7 million, each up 21% year over year.

Eikon dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial, and submitted an IND application for EIK1006. It also reported EIK1003 and EIK1004 clinical data and preliminary EIK1005 results, and appointed Ching-Pin Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. A prespecified TeLuRide-008 interim analysis for dose selection is anticipated in the second half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
current report
-
Rhea-AI Summary

Eikon Therapeutics, Inc. (EIKN) presented updated TeLuRide-005 data for EIK1001 with pembrolizumab and histology-appropriate chemotherapy in previously untreated stage 4 non-small cell lung cancer. At the October 1, 2026 efficacy cutoff, the 65-person efficacy-evaluable population had a 63.1% objective response rate and an 89.2% disease control rate, with median follow-up of 17.2 months. The squamous cohort had a 72.4% response rate, 100% disease control rate, and 12.9-month median duration of response; the non-squamous cohort had rates of 55.6% and 80.6%, respectively, and an 11.2-month median duration of response.

At the July 13, 2026 safety cutoff, 48.6% of the 72-person safety-evaluable population experienced Grade 3 or higher treatment-related adverse events, and 6.9% discontinued treatment due to these events. Cytokine release syndrome events were Grade 1 or 2, with no Grade 3 or higher events; no treatment-related adverse events led to death.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.69%
Tags
current report
Rhea-AI Summary

Eikon Therapeutics, Inc. (EIKN) reported initial and updated Phase 1/2 data for PARP1 inhibitors EIK1003 and EIK1004 and WRN helicase inhibitor EIK1005 at the 2026 ESMO Congress. EIK1003 objective response rates were 14.3% (7/49) in monotherapy Cohort 1A, 20.8% (5/24) with abiraterone in Cohort 1B, and 26.4% (14/53) with paclitaxel in Cohort 1C; Cohort 1A’s rate was 31.3% (5/16) among PARP-naïve participants.

In Cohort 1C, Grade 3 or higher treatment-emergent adverse events occurred in 80.3% (49/61), and events led to dose interruptions in 86.9% (53/61). EIK1004 had Grade 3 or higher events in 17.6% (12/68) and an objective response rate of 12.1% (7/58). EIK1005 monotherapy had stable disease in 6 of 8 assessed participants, including one participant with stable disease ongoing for over 8 months; its single participant on pembrolizumab had a partial response.

Eikon is enrolling EIK1003 Cohort 1D; initial data and completion of Phase 2 dose optimization are expected in the second half of 2027. Initial results from an EIK1004-docetaxel combination are planned for the second half of 2027. EIK1005-pembrolizumab results are expected in the first half of 2027, with complete monotherapy results expected in the second half.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.89%
Tags
current report
-
Rhea-AI Summary

Eikon Therapeutics, Inc. (EIKN) is the issuer named in an amended beneficial-ownership report by FMR LLC and Abigail P. Johnson. FMR LLC reports beneficial ownership of 5,520,152 common shares, or 10.2% of the class, with sole voting power over 5,518,822 shares and sole dispositive power over 5,520,152 shares.

Abigail P. Johnson, also identified as a reporting person, reports zero voting power and sole dispositive power over 5,520,152 shares. The report states that other persons may have rights to dividends or sale proceeds, but no other person's interest exceeds 5% of the common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.40%
Tags
ownership
-
Rhea-AI Summary

Eikon Therapeutics, Inc. is the issuer in an amended beneficial-ownership report showing 1,147,138 common shares, or 2.1%, attributed to Abu Dhabi Investment Authority (ADIA) and its wholly owned subsidiary, Platinum Falcon B 2018 RSC Limited. Platinum Falcon directly owns the shares, while ADIA may be deemed their beneficial owner; each reports shared voting and dispositive power over the same 1,147,138 shares and zero sole voting or dispositive power.

The 2.1% calculation is based on 54,165,030 Eikon shares outstanding as of August 3, 2026. The reporting persons identify themselves as owning 5% or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
ownership
Rhea-AI Summary

Eikon Therapeutics, Inc. (EIKN) received a Form 4 filing from an investor group associated with The Column Group reporting an open-market purchase of 89,200 shares of Common Stock on September 3, 2026 at a weighted average price of $11.5588 per share. The purchased shares are directly held by Peter Svennilson, while affiliated Column Group funds report indirect holdings of 4,312,139; 148,840; and 1,319,164 shares, and the reporting persons may be deemed to share voting and investment power but each disclaims beneficial ownership beyond their pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
insider
-
Rhea-AI Summary

Eikon Therapeutics provides a detailed update on its clinical-stage pipeline and technology platform. The company describes EIK1001, a TLR7/8 dual-agonist being tested in the Phase 2 TeLuRide-005 NSCLC study, where objective response rate was 63.1% and disease control rate 90.8% across 65 efficacy-evaluable participants as of May 4, 2026, with generally manageable safety alongside pembrolizumab and chemotherapy. A Phase 2/3 registrational melanoma trial (TeLuRide-006) and a Phase 2/3 NSCLC trial (TeLuRide-008) are underway with multiple data readouts and interim analyses planned between the second half of 2026 and the first half of 2027.

The update also highlights EIK1003, a PARP1-selective inhibitor, showing monotherapy objective response rate of 14.3% (7 of 49 evaluable participants) and 24.5% in combination with paclitaxel (13 of 53), with no treatment-related deaths reported. EIK1005, a WRN inhibitor for MSI-high cancers, has early clinical safety data supporting a 50 mg starting dose and a half-life of 9.4 days. EIK1006, an AR antagonist, is progressing through preclinical work toward a projected IND submission by the end of 2026. Eikon emphasizes its single-molecule tracking technology, machine-learning–guided design, and an experienced leadership team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
current report
-
Rhea-AI Summary

Eikon Therapeutics, Inc. is a late clinical-stage biopharmaceutical company developing medicines using a proprietary imaging and data platform. For the quarter ended June 30, 2026, it reported a net loss of $88.4 million, compared with $105.2 million a year earlier, driven mainly by research and development expense of $75.5 million and general and administrative expense of $17.9 million.

As of June 30, 2026, Eikon held cash, cash equivalents, and marketable securities of $531.2 million and total assets of $779.6 million, and had an accumulated deficit of about $1.1 billion. Management states these resources are sufficient to fund operations for at least one year. The company completed an IPO in February 2026, issuing 21.2 million shares at $18.00 per share, and converted all redeemable convertible preferred stock into common stock. Eikon discloses a material weakness in internal control over financial reporting linked to a prior-period restatement and outlines plans to remediate it while continuing to advance multiple product candidates, including EIK1001–EIK1006.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
quarterly report
Rhea-AI Summary

Eikon Therapeutics, Inc. reported second quarter 2026 results and extensive clinical progress across its oncology pipeline. The company ended the quarter with $531.2 million in cash, cash equivalents and marketable securities and expects this balance to fund operations into the second half of 2027. Net loss attributable to common stockholders was $88.4 million, compared with $105.2 million a year earlier.

Research and development expenses for the quarter were $75.5 million, up from $69.2 million, reflecting increased clinical trial activity. General and administrative expenses declined sharply to $17.9 million from $40.5 million, primarily due to prior-year impairments that did not recur. Total stockholders’ equity improved to $466.5 million at June 30, 2026, from a deficit of $(879.0) million at December 31, 2025.

Clinically, Eikon highlighted seven accepted abstracts for ESMO 2026 covering all four current clinical candidates, encouraging combination data for EIK1001 in NSCLC and melanoma, and advancing Phase 1/2 programs for PARP1 inhibitors EIK1003 and EIK1004, WRN helicase inhibitor EIK1005, and planned IND submission for AR antagonist EIK1006 by year-end 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
current report

FAQ

How many Eikon Therapeutics (EIKN) SEC filings are available on StockTitan?

StockTitan tracks 41 SEC filings for Eikon Therapeutics (EIKN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Eikon Therapeutics (EIKN)?

The most recent SEC filing for Eikon Therapeutics (EIKN) was filed on November 12, 2026.